Effect of Amiloride and Spironolactone on Renal Tubular Function, Ambulatory Blood Pressure, and Pulse Wave Velocity in Healthy Participants in a Double-Blinded, Randomized, Placebo-Controlled, Crossover Trial
Effect of Amiloride and Spironolactone on Renal Tubular Function, Ambulatory Blood Pressure, and Pulse Wave Velocity in Healthy Participants in a Double-Blinded, Randomized, Placebo-Controlled, Crossover Trial
复制标题
DOI：
10.3109/10641963.2012.681730
复制
发表时间：
2012-01-01
影响因子：
12.3
通讯作者：
Pedersen, Erling Bjerregaard
中科院分区：
文献类型：
--
作者：
Matthesen, Solveig Klok;Larsen, Thomas;Pedersen, Erling Bjerregaard
我们想验证以下假设：阿米洛利或螺内酯治疗降低了动态血压（ABP）和中心血压（CBP），速尿治疗后通过ENaC γ和AQP2的小管转运增加。在基线条件下，ABP、CBP、肾小管功能或血管活性激素的血浆浓度没有差异。经速尿治疗后，观察到CBP、CH(2)o、FENa、FEK、u-AQP2/min、u-ENaC γ /min、PRC、p-Ang II、p-Aldo升高。速尿治疗后AQP2和ENaC对水钠的吸收增加很可能是拮抗水钠耗竭的代偿现象。
We wanted to test the hypothesis that treatment with amiloride or spironolactone reduced ambulatory (ABP) and central blood pressure (CBP) and that tubular transport via ENaC gamma and AQP2 was increased after furosemide treatment. During baseline conditions, there were no differences in ABP, CBP, renal tubular function, or plasma concentrations of vasoactive hormones. After furosemide treatment, an increase in CBP, CH(2)o, FENa, FEK, u-AQP2/min, u-ENaC gamma/min, PRC, p-Ang II, and p-Aldo was observed. The increases in water and sodium absorption via AQP2 and ENaC after furosemide treatment most likely are compensatory phenomena to antagonize water and sodium depletion.